AUG 0 8 2008 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE WEISS Lola et al Serial No.: 10/589,623 Filed: August 16, 2006 For: TREATING OR PREVENTING DIABETES WITH CANNABIDIOL Examiner: WEISS Lola et al S Group Art Unit: Attorney Docket: 32361

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

The undersigned states:

any communication	ch item of information contained in the information disclosure statement was first cited in from a foreign patent office in a counterpart foreign application not more than three months the information disclosure statement; or
communication from person signing the conformation disclosi	item of information contained in the information disclosure statement was cited in a n a foreign patent office in a counterpart foreign application, and, to the knowledge of the pertification after making reasonable inquiry, no item of information contained in the are statement was known to any individual designated in 37 CFR 1.56(c) than three months the information disclosure statement.
Ple	ease charge the fee set forth in 37 CFR 1.17 (p) to Deposit Account 501407.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan Registration No. 40,338

Dated: July 15, 2008